Porencephaly …

Tiziana Granata MD

Developmental Malformations

Updated 04.09.2024
Released 07.12.1994
Expires For CME 04.09.2027

Porencephaly

Author: Tiziana Granata MD

See Contributor Disclosures

Editor: Harvey B Sarnat MS MD FRCPC

Porencephaly

In This Article

Quick Link

Introduction

Overview

Porencephaly, an encephaloclastic brain lesion, is one of the most frequent causes of infantile cerebral palsy. This lesion results mainly from ischemic insults occurring in late pregnancy or in early postnatal life or from intrauterine exposure to infections and toxins. The identification of mutations in the COL4A1 and COL4A2 genes, which encode the type IV alpha1 and alpha2 collagen chains, has demonstrated that a subset of porencephaly may be genetically determined. In this article, the author reviews the clinical features and the pathogenetic aspects of porencephaly and provides an update on the pathophysiology of this disorder. Moreover, the author summarizes findings on the role of mutations in COL4A genes in determining small vessel disease and brain malformations. The phenotypic spectrum of mutations of the COL4A genes, which besides cerebrovascular damage may include systemic involvement with ocular, renal, muscular, and cardiac features, is progressively widening. COL4A1/2 gene mutations, originally reported to be associated with familial porencephaly, are in fact increasingly recognized as causative genes of an array of brain malformations, including schizencephaly, polymicrogyria, and subependymal heterotopia, as well as of minor, nonspecific brain abnormalities.

Key points

	• Porencephalies are focal cavitary lesions frequently communicating with the lateral ventricles; they result from brain destruction during late fetal or early postnatal developmental stages.
	• The more common etiologic factors are ischemic and hemorrhagic insults, but toxic agents, infections, trauma, and drugs have also been reported.
	• Porencephaly may also be due to dominant mutations (either inherited and de novo) of genes COL4A1 and COL4A2 encoding for type IV collagen alpha-1 and for type IV collagen alpha-2, respectively. The type IV collagen, which is a component of nonfibrillary collagen, is a main constituent of the basement membrane of many tissues, among them vascular endothelia.
	• The clinical expression of the porencephaly depends on its site, its size, and the timing of the causative insult. Clinical symptoms include motor deficits, intellectual impairment, and seizures.
	• The management of porencephaly is that of the associated clinical manifestations: cerebral palsy, intellectual impairment, and seizures. Management includes rehabilitation and antiepileptic treatment. Patients with drug-resistant epilepsy may benefit from respective surgery, which may consist of functional hemispherectomy in patients with large, hemispheric cysts.
	• Genetic counseling is appropriate in familial and genetically determined porencephaly. Special attention in genetic counseling must be paid for families carrying COL4A mutations, given the variable phenotypic expression and penetrance.

Historical note and terminology

The term "porencephaly" (from the Latin word porus, meaning "communication") was first introduced by Heschl in 1859 to describe clefts or cavities in the cerebral mantle (28). He attributed these lesions to destruction of the developing brain. Since Heschl's first description, the term "porencephaly" has been widely used to describe etiologically different brain cavities communicating with either the subarachnoid space or the lateral ventricles.

The present understanding of the term "porencephaly" is still debated. Most authors recognize two major subgroups: (1) developmental or true porencephaly, and (2) congenital or encephaloclastic porencephaly. The former refers to cases characterized by full-thickness defects of cortical mantle associated with polymicrogyria or heterotopic gray matter. For these cases, however, the term "schizencephaly" is preferred (22). The second subgroup refers to lesions arising from cortical destruction in the developing brain. Reports of COL4A1 and COL4A2 mutations, both in porencephaly and schizencephaly, suggest that a common genetic mechanism may be responsible for brain damage at least in a subset of patients (74; 09). Nevertheless, from a clinical point of view, schizencephaly and porencephaly must be differentiated because the MRI pictures, the clinical and epileptic phenotypes, and the outcome have distinctive features.

Clinical manifestations

Presentation and course

The clinical expression of the encephaloclastic porencephaly depends on its site, its size, and the timing of the causative insult. Clinical findings are intellectual impairment, seizures, and various forms of cerebral palsy, including spastic hemiparesis, diplegia, and quadriplegia.

Decorticate posture

The posture of spastic hemiparesis: the affected upper extremity is held in adduction and flexion; the affected foot is held in plantar flexion and inversion. Spasticity prevents resumption of normal posture. (Courtesy of Dr. Sid ...

Pregnancy is usually uneventful, although in severe cases, decrease in fetal movements may be reported by the mother or detected by ultrasonography. In few cases, the delivery may be complicated, leading to the wrong diagnosis of perinatal hypoxic-ischemic damage. The porencephalic cyst that follows intraventricular hemorrhage in the preterm infant manifests at birth with nonspecific symptoms, such as decreased alertness, irritability, irregular respiratory rhythm, hypotonia, and seizures. The long-term clinical symptoms are hemiplegia or asymmetric diplegia with greater involvement of the leg, and cognitive difficulties (68). Term infants may exhibit no symptoms or signs at birth. When symptoms manifest, they are represented in most cases by focal motor seizures, or slight hemiparesis, contralateral to the involved side. The long-term clinical outcome again depends on the site and size of porencephaly. Children with mild lesions may have improvement or even disappearance of motor deficit by the age of 2 years. Children with more extended lesions may develop hemiplegic or tetraplegic cerebral palsy. Intellectual impairment is present in about one third of unilaterally affected children and in most patients with bilateral involvement (68; 62).

Epilepsy may manifest as West syndrome in the first year of life or as partial epilepsy later in childhood (63; 75). Infantile spasms are usually controlled by steroid therapy, but partial seizures can subsequently appear, particularly in infants with frontal lobe involvement. In childhood, epilepsy occurs in about one third of term infants with focal brain damage, whereas it is uncommon in preterm children with intraventricular hemorrhage (68). In most patients, epilepsy is characterized by partial seizures whose semeiology is consistent with the epileptogenic area located close to porencephaly. Epilepsy usually starts during childhood; only a few patients with seizure onset during adulthood have been reported (49; 52). A minority of patients with circumscribed MRI lesion may show a more diffuse epileptogenicity, (related to a widespread brain damage or resulting by secondary bilateral synchrony of frontal foci) with tonic and atonic seizures (08).

A peculiar epileptic syndrome frequently present in patients with porencephaly, likewise in patients with hemiplegic cerebral palsy resulting from congenital (or acquired early in life) unilateral brain damage is startle epilepsy (07). In startle epilepsy, sudden tonic contraction of the paretic limbs are induced by auditory, or less frequently, somatosensory stimuli. The reflex seizures are brief, lasting less than 30 seconds, but usually frequent and may determine falls to the ground, thus, impairing the everyday life. The ictal EEG of reflex seizures is characterized by a vertex high voltage discharge followed by diffuse flattening or low amplitude 6 to 11 Hz activity. In most cases, startle epilepsy is refractory to antiepileptic drugs. Sporadic unprovoked seizures, mostly of focal type, are associated and usually precede the onset of startle epilepsy.

Prognosis and complications

Prognosis depends on the severity of the associated static encephalopathy or seizure disorder. The general prognostic criteria for motor and mental functions are those of cerebral palsy (68). Severe and long-lasting symptoms in the first days of life and difficult-to-treat neonatal seizures are unfavorable prognostic factors. EEG recordings, CT, and cranial ultrasonographies may contribute as early prognostic factors. Occurrence and prognosis of epilepsy is related to the site of clastic damage. In preterm infants with porencephaly following periventricular hemorrhage, and in term infants with circumscribed lesions involving the rolandic or parieto-occipital regions, spasms and later focal seizures are easily controlled by treatment. A less favorable course is common in children with extensive porencephaly and cerebral atrophy, particularly when the frontal lobes are involved. Childhood-onset partial epilepsy, occurring in about one third of hemiplegic patients with focal cortical disruption, is medically treatable in about 80% of cases (68). Mesial temporal sclerosis has been described in a few patients with porencephaly and intractable seizures; this finding suggests that in these patients the altered hippocampus is the likely seizure focus and that surgical treatment may be indicated (06). If the porencephalic cyst progressively expands, progressive neurologic impairment may appear together with signs of raised intracranial pressure.

In patients with COL4A1 or COL4A2, the possibility of spontaneous intracerebral hemorrhages and strokes in childhood and adulthood must be considered (25).

Clinical vignette

The boy was born by Cesarean section at 30 weeks' gestation for acute fetal distress due to abruptio placentae. Weight at birth was 1215 g. The Apgar scores were 2 and 5 after 1 and 5 minutes, respectively. The infant had anemia, transient renal failure, hemorrhagic colitis, and respiratory distress requiring assisted ventilation. Transcranial ultrasonography at birth showed a right periventricular hyperechogenic area. Serial examinations in the following weeks demonstrated posterior enlargement of the lateral ventricles and cystic cavitation communicating with the right lateral ventricle. The presence of porencephaly was later confirmed by MRI.

Right porencephalic cyst (MRI)

The lateral ventricles are enlarged; the porencephalic cyst communicates with the central part of the right lateral ventricle. (Contributed by Dr. Tiziana Granata.)

Neonatal EEG recordings were consistently characterized by focal slow and sharp waves over the right hemisphere. The newborn was hyperexcitable, and a mild left hemiparesis was evident.

General condition progressively improved, and the infant was discharged by neonatal care at 2 months of age. Spastic tetraparesis, more severe on the left side, then became evident, associated with motor and cognitive delay. At the corrected age of 6 months, infantile spasms occurred. The EEG recordings showed right hemihypsarrhythmia.

Right hemihypsarrhythmia (EEG)

The asterisk marks a spasm during light slow sleep, with brief tonic discharge of the left deltoid muscle. Sleep spindles are evident on the left hemisphere before the spasm occurs. (Contributed by Dr. Tiziana Granata.)

Steroid treatment led to disappearance of spasms and hypsarrhythmia. No seizures occurred in the follow-up period. By the age of 4 years, spastic tetraparesis was still evident, but motor and cognitive skills were slowly improving.

Biological basis

Etiology and pathogenesis

Porencephalies are due to encephaloclastic brain lesions occurring from the late second trimester of gestation to the first postnatal days or weeks (58). Porencephaly is not due to a single etiology, and various factors, both genetic and acquired, contribute to its occurrence. Porencephalies have been reported in association with maternal exposure to toxins, infections, and drugs.

Intraventricular hemorrhage in the preterm infant may obstruct the terminal vein in the subependymal region, leading to hemorrhagic infarction and formation of porencephalic cysts. In the twin embolization syndrome, embolic phenomena or thromboplastin release from the deceased to the surviving twin through the monochorionic placenta may result in porencephaly (53; 39). Porencephaly has also been rarely reported in association with developmental failure of cerebral venous sinuses and linear sebaceous nevi, pyknodysostosis, neonatal intravascular transfusion for Rhesus alloimmunization, alloimmune thrombocytopenic purpura, deficiencies in the protein C anticoagulant pathway, and factor V Leiden mutation. The role of coagulation abnormalities is supported by the high prevalence of prothrombotic risk factors, either isolated or combined, observed in patients with porencephaly. A case-control study has demonstrated a significantly higher prevalence of FV G1691A mutation (factor V Leiden mutation) and of multiple prothrombotic defects in a large series of patients with porencephaly compared to controls (12). The presence of at least one prothrombotic abnormality has also been reported in 60% of children with perinatal stroke (38).

Genetics. A possible genetic origin of a subset of porencephaly had been suggested by the report of a few familial cases and then confirmed by the identification of a locus for familial porencephaly on chromosome 13qter. In 2005, Gould and coworkers, using a mouse model generated by random mutagenesis, characterized a novel mutant mouse with severe perinatal cerebral hemorrhage resulting in porencephaly (19). The genetic abnormality was found to reside in a defect in collagen IVA1 (COL4A1), a major component of the vascular basement membrane (19; 35). COL4A1 forms a sheet-like network beneath the endothelium and surrounding smooth muscle cells with a role in the formation of basement membranes during embryogenesis, in the cohesiveness of basement membrane, and in preservation of vascular tone and endothelial cell function (51; 71). The mutant mice bearing COL4A1 mutations (namely, in-frame deletion of exon 40) had severe cerebral hemorrhage, were smaller than controls, and could associate ocular and renal abnormalities. Homozygous mutant mice were not viable after midembryogenesis; half of the heterozygous died in the first day of life, and about 18% of adult heterozygous had porencephalic lesions. Structural integrity of the vascular basal membrane was demonstrated to be impaired in this animal model, resulting in vessel susceptibility to disruption, and supporting a possible predisposition of this animal model toward cerebral hemorrhage. Because not all mutant mice developed porencephaly, it has been suggested that environmental factors, such as birth trauma, could interact with the genetic background in determining the outcome (19); this hypothesis was supported by the fact that perinatal hemorrhages were dramatically reduced by surgical delivery of mutant pups (20). The concurrent role of environmental factors, including delivery-induced stress, is in line with the observation that in patients harboring COL4A1 mutations, the hemorrhage may develop during the first few days of a complicated neonatal course. It is also supported by the report of a sporadic case of a boy with a history of infantile hemiparesis who experienced recurrent intracerebral hemorrhage during sport activities (70).

However, parenchymal hemorrhage may also occur during fetal life, and the mutation itself may be responsible for the brain damage as initially demonstrated by the antenatal onset of parenchymal hemorrhage in two preterm siblings (13; 14).

Following the initial description of COL4A1 mutations in the animal model and in familial porencephaly, the crucial role of type IV collagen alpha 1 in preserving the integrity of the vascular basement membrane has been increasingly investigated, and different mutations of the COL4A1 gene have been identified. Correspondingly, the clinical phenotype of COL4A1 mutations has also widened in different members of a given affected family. The disorder related to COL4A1 mutations is now considered a systemic disease, which involves brain, kidney, eyes, heart, and skeletal muscles (44; 50).

Dominant, inherited, or apparently de novo mutations in the COL4A2 gene have also been identified in patients with porencephaly and other cerebrovascular disorders, such as periventricular leukoencephalopathy, cerebral aneurysm, intracerebral hemorrhage, and small vessel disease, isolated or associated with ocular abnormalities (34; 72; 73; 25; 26). COL4A2, which encodes for the type IV alpha 2 collagen chain, is structurally and functionally associated with COL4A1. Both genes are ubiquitously expressed, they are regulated by the same promoter, and the encoded procollagen alpha1 and alpha2 chains form a heterotrimeric helix with a constant 2:1 ratio (alpha1 alpha1 alpha2). The putative role of COLA42 mutations in determining vascular accident is supported by experimental data from animal models; mutant Col4α2 mice feature defects in the eye, brain, and vascular stability with focal brain hemorrhagic lesions that are similar to those observed in mutant Col4α1mice (15).

A report based on clinical and genetic data of a personal series and on a thorough literature review has provided an overview of the phenotypic and genotyping spectrum of disorders related to COL4A1 and COL4A2 mutations (44). The authors report their own series of 21 COL4A1 and three COL4A2 mutations, with a high percentage of de novo mutations. A high rate of de novo mutations is also reported in the literature: among 67 families (60 with COL4A1 and seven with COL4A2 mutations) 25% of cases carried a de novo mutation and 50% an inherited (no parental data were available in the remaining 25% of cases).

The study confirms the wide phenotypic spectrum of COL4A-related disorders that are noted in the following table:

	1. Prenatal and neonatal intracerebral hemorrhage. Porencephaly is the most frequent brain damage observed, isolated, or associated with intracranial calcification, hemolytic anemia, elevated creatine kinase, myopathy, ophthalmologic features, and hematuria.
	2. Extensive bilateral porencephaly resembling hydranencephaly.
	3. Periventricular leukomalacia with intracranial calcifications in periventricular areas, basal ganglia, or deep white matter, also in absence of porencephaly.
	4. Ocular manifestations consisting of retinal small vessel tortuosity, cataract, and anterior segment dysgenesis, always associated with leukoencephalopathy and small vessel disease.
	5. HANAC syndrome (hereditary angiopathy with nephropathy, aneurysms, and cramps), which is due to mutations in COL4A1 affecting glycine residues in close proximity of exons 24 and 25, and which constitutes a distinctive phenotype dominated by the systemic symptoms, in absence of porencephaly. In this syndrome, the angiopathy manifests with retinal vessel arterial tortuosity and cerebral vessel disease with aneurysm of the carotid syphon; the kidney manifestations include persistent hematuria or proteinuria with or without renal cysts. An additional characteristic symptom is the presence of painful muscle cramps with elevated creatine kinase.
	6. Stroke in childhood and young adulthood.
	7. Sporadic late-onset hemorrhagic stroke.

In the last few years, several reports further widened the phenotypic spectrum of COL4A1- and COL4A2-related disorders. Studies have clarified that mutations in these genes may cause an array of brain malformations, including schizencephaly, polymicrogyria (either isolated or associated to porencephaly), and subependymal heterotopia (74; 09; 57; 47; 64).

Moreover, the growing use of next-generation sequencing techniques has led to the identification of patients harboring COL4A1 and COL4A2 mutations with epilepsy as their main clinical problem. In these patients, MRI did not detect brain malformations nor porencephaly, but only nonspecific findings such as asymmetric ventricular enlargement, diffuse periventricular leukoencephalopathy, and white matter thinning (77).

A further possible cause of genetic porencephaly has been reported by Sato and colleagues (56). In this paper, the authors reported on an infant carrying a novel missense mutation in the TUBA1A gene. Her MRI showed a complex and diffuse brain malformation characterized by a simplified gyral pattern with areas of focal polymicrogyria and porencephaly. Tubulin-related genes regulate neuronal migration and axonal guidance; therefore, brain malformations due to mutations in these genes are typically complex and may involve multiple cortical and subcortical structures (01). However, porencephaly has never been associated with tubulinopathies. Should this association be confirmed by further observations, including tubulin-related genes in the genetic testing for patients with porencephaly will be considered (56).

Finally, homozygous variants in COLGALT1 gene have been reported in a patient with a severe form of congenital porencephaly and leukoencephalopathy. The clinical picture was characterized by severe spastic tetraparesis, developmental delay, and refractory epilepsy (66).

COLGALT1 encodes for CoLGalT1, a galactosyltransferase that initiates glycosylation of collagen. The reduced ColGalT activity might decrease COL4A1 production or glycosylation and cause the fragility of vascular basement membrane (45).

Pathology. A porencephalic cyst is the result of focal necrosis occurring in the developing brain. The pathogenetic mechanisms leading to porencephaly are related to ischemic or hemorrhagic lesions in most cases, and it should be emphasized that the timing of the insult is more important than the type of the insult in determining brain cavitation in the developing brain (54). Several factors are important in facilitating cyst formation from the late second trimester of gestation to the first postnatal stages. The higher water content, the larger vascular territories with insufficient collateral circulation, and the limited capacity to establish adequate gliotic scarring for the smaller number of mature astrocytes are all typical features of the immature brain in this developmental phase, contributing to its higher propensity to cavitation (54).

Porencephaly communicates with the lateral ventricle. Imaging studies often give the impression that the cavity also communicates with the subarachnoid space overlying the cerebral hemisphere, but pathologically the pial membrane, and often some of the arachnoid, is nearly always preserved and prevents the free communication of fluid between the two spaces, though this membrane is so thin that it is below the resolution of CT or MRI. Loculated cysts within the deep white matter of the cerebrum that do not communicate with the ventricle are not porencephalic by definition. The walls of the cyst are smooth and not covered by reactive gliosis. The basal ganglia, cerebellum, and brainstem are usually not involved, but the thalamus may be small for the hypoplasia of the thalamic nuclei projecting to the affected cortex. Secondary degeneration of descending fiber systems, particularly the corticospinal tracts, depends on the location and extent of the lesion (16). Porencephalic cysts are often surrounded by a zone of polymicrogyria. These gyri are atrophic secondary to ischemia during development and, therefore, do not represent a primary disturbance of neuroblast migration or other primary malformations as does pachygyria. This polymicrogyria may or may not be evident by MR imaging. The gray matter surrounding porencephaly undergoes structural and functional changes for a prolonged period of time after the original injury (40). A further type of cortical malformation that may be observed in surviving cerebral cortical tissue adjacent to a porencephalic cyst is focal cortical dysplasia. In this case, the dysplasia results from a "maturational arrest" caused by the ischemic cerebral insult that was not so severe to include this zone in the frank infarction but that is severe enough to prevent maturation of the cortical lamination or transition from micro-columnar to laminar architecture shortly after midgestation (55; 04). This type of malformation, together with the other dysplasia that occurs adjacent to lesions acquired during early life, is termed focal cortical dysplasia IIId (05).

Neuropathological studies in fetuses carrying COL4A1–A2 mutations demonstrate the presence of hemorrhagic encephalopathy, which was constantly associated with post-ischemic damage in grey and white matter that can worsen throughout the pregnancy (42; 61; 24). At the pathological examination, the multifocal hemorrhagic lesions of different ages were found close to capillaries and small vessels with discontinuous walls, in agreement with the known small vessel fragility due to COL4A diseases.

Prevention

Prenatal and perinatal care may reduce the risk of porencephaly. Prevention of intrauterine asphyxia and prematurity, avoidance of toxins and infection during pregnancy, and close monitoring of the high-risk fetus during labor and delivery are of major importance. Recognition of maternal risk factors must lead to appropriate monitoring and, when available, treatment. Pregnancy at risk for fetal and neonatal alloimmune thrombocytopenia (ie, women with positive family history of the disorder, or who had a previous affected neonate) should be referred to a specialized center where information can be given about the risk of fetal hemorrhage, along with the benefits and risks of management strategies. With this regard, a characteristic antenatal and early postnatal neuroimaging pattern (ie, large hemispheric porencephaly associated with lateral ventriculomegaly) has been described in neonatal alloimmune thrombocytopenia (11). Recognition of this pattern could be useful in prompting the diagnosis and treatment in order to prevent the catastrophic sequelae of neonatal alloimmune thrombocytopenia in both the index case and subsequent offspring. Prenatal ultrasonography and /or MRI in a large cohort of patients harboring COL4A1/A2 variants detected the following characteristics: fetal ventriculomegaly with increased echogenicity and irregularity of the ventricular walls, deformed frontal horn, cerebellar anomaly, and fetal growth restriction (33; 24). In pregnant women carrying COL4A1 mutations, cesarean section is in fact recommended to reduce the risk of vascular injury to the newborn as a result of birth trauma (70).

The possibility of familial occurrence from either maternal or genetic causes and the possible association with cerebral and extracerebral malformation must be considered.

An accurate family history and examination must also be performed in apparently isolated cases to identify possible carriers of cerebral small vessel disease (69). In families carrying COL4A1 or COL4A2 mutations, genetic counseling is warranted. Genetic counseling must consider the high intra-familial variability of COL4A-related disorders, with a wide range of phenotypes and the apparent incomplete penetrance, as well as the possibility of de novo mutations (18; 65; 43).

Couples who already have an affected child must be investigated for the mutation, and if one of the two parents carries the mutation, the couple should be informed of the risk for any following pregnancies.

Few authors reported on prenatal diagnosis of COL4A1 gene mutations detected on fetal DNA from amniotic fluid (17; 36). As underscored by Garel and colleagues, given that the prenatal identification of this autosomal dominant gene raises ethical and medical questions concerning both the fetus (given the wide range of clinical presentation) and the parents, parental consent for the genetic analysis requires complete and clear information (17). Identifying the asymptomatic carrier implies obtaining the correct information about the risk for stroke in the carrier and his/her family. At-risk pregnancy requires accurate follow-up with ultrasound (and, when available, MRI) evaluation of the fetus. Cesarean delivery is recommended to decrease the risk of perinatal hemorrhagic events in the baby and in the mother when she carries the mutation.

Diagnostic workup

The diagnosis of porencephaly is made through imaging techniques. Prenatal ultrasonography can detect intracranial hemorrhage and the cystic lesions in the fetus’ brain (67). Porencephaly should also be suspected when isolated cerebral ventriculomegaly is consistently detected in the late stages of pregnancy (03).

Porencephaly, along with other brain abnormalities, may be detected by prenatal MRI. Fetal MRI should be considered a valuable diagnostic tool when ultrasonography is doubtful (for example when it only shows ventriculomegaly) and in selected at-risk pregnancies because it can give a more precise characterization of the lesions in the cerebral parenchyma and detect associated malformations (03; 10; 76; 27; 57).

In preterm infants, serial cranial ultrasonographies demonstrate increased periventricular echogenicity and, some weeks later, cystic formation, periventricular leukomalacia, and ventriculomegaly. In term newborns, a focal area of increased echogenicity is then replaced by cystic cavitation. In older infants, CT scans reveal porencephaly as a circumscribed area of hypodensity, often associated with cerebral atrophy of varying degrees. On MRI, porencephalies appear as smooth-walled cavities with no internal structure, lined by white matter. MRI demonstrates the convolutional pattern of the surrounding cortex, as well as the presence of gliosis and white matter injury; it distinguishes porencephaly from other clastic encephalopathies (multicystic encephalomalacia, hydranencephaly, "basket brain") and true brain malformations (schizencephaly). The prenatal and early postnatal imaging findings in infants with serologically proved alloimmune thrombocytopenia are characterized by large hemispheric porencephaly associated with lateral ventriculomegaly (11).

In patients harboring COL4A1 mutations, with or without porencephaly, MR images may demonstrate changes in the periventricular and deep white matter with sparing of U fibers, and irregular dilatation of the lateral ventricles. MRI and CT scans may also show spot and linear calcification in the subependymal region and around areas of porencephaly in the deep cerebral white matter and the basal ganglia (37).

Mutational analysis of the COL4A1 and COL4A2 genes should be ideally performed in all infants with porencephaly of unknown cause, especially if retinal vascular tortuosity, congenital cataract, or renal cysts are associated or if the family history is positive for the symptoms included in the COL4A1 – COL4A2 phenotypes (69; 72; 73; 23). In a case suspected or proven to have COL4A1 or COL4A2 mutations, a comprehensive evaluation aimed at detecting the possible involvement of the eyes, kidneys, heart, skin, and muscles must be performed. The following investigations have been proposed: evaluation of visual acuity, funduscopy, and slit-lamp examination; renal ultrasound scan or MRI; searching for proteinuria and hematuria; EKG; and creatine kinase (60).

Media

References

01: Bahi-Buisson N, Cavallin M. Tubulinopathies overview. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 2016.
02: Barkovich AJ. Pediatric neuroimaging. New York: Raven, 1990:35-75.**
03: Benacerraf BR, Shipp TD, Bromley B, Levine D. What does magnetic resonance imaging add to the prenatal sonographic diagnosis of ventriculomegaly. J Ultrasound Med 2007;26(11):1513-22. PMID 17957045
04: Blumcke I, Sarnat HB, Coras R. Surgical Neuropathology of Focal Epilepsies: Textbook and Atlas. Mountrouge, France: John Libbey Eurotext, 2015.
05: Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011;52(1):158-74. PMID 21219302
06: Burneo JG, Faught E, Knowlton RC, et al. Temporal lobectomy in congenital porencephaly associated with hippocampal sclerosis. Arch Neurol 2003;60(6):830-4. PMID 12810487
07: Caraballo R, Semprino M, Cersosimo R, Sologuestua A, Arroyo HA, Fejerman N. Hemiparetic cerebral palsy and startle epilepsy. Rev Neurol 2004;38(2):123-7. PMID 14752709
08: Carreno M, Kotagal P, Perez Jimenez A, Mesa T, Bingaman W, Wyllie E. Intractable epilepsy in vascular congenital hemiparesis: clinical features and surgical options. Neurology 2002;59(1):129-31. PMID 12105322
09: Cavallin M, Mine M, Philbert M, et al. Further refinement of COL4A1 and COL4A2 related cortical malformations. Eur J Med Genet 2018;61(12):765-72. PMID 30315939
10: Colin E, Sentilhes L, Sarfati A, et al. Fetal intracerebral hemorrhage and cataract: think COL4A1. J Perinatol 2014;34(1):75-7. PMID 24374867
11: Dale ST, Coleman LT. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging findings in the pediatric brain. Am J Neuroradiol 2002;1457-65. PMID 12372732
12: Debus OM, Kosch A, Strater R, Rossi R, Nowak-Gottl U. The factor V G1691A mutation is a risk for porencephaly: A case-control study. Ann Neurol 2004;56(2):287-90. PMID 15293282
13: de Vries LS, Koopman C, Groenendaal F, et al. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann Neurol 2009;65(1):12-8. PMID 19194877
14: Durrani-Kolarik S, Manickam K, Chen B. COL4A1 mutation in a neonate with intrauterine stroke and anterior segment dysgenesis. Pediatr Neurol 2017;66:100-3. PMID 28043398
15: Favor J, Gloeckner CJ, Janik D, et al. Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles. Genetics 2007;175(2):725-36. PMID 17179069
16: Friede RL. Developmental neuropathology. 2nd ed. New York: Springer-Verlag, 1989:28-43.**
17: Garel C, Rosenblatt J, Moutard ML, et al. Fetal intracerebral hemorrhage and COL4A1 mutation: promise and uncertainty. Ultrasound Obstet Gynecol 2013;41(2):228-30. PMID 22811259
18: Giorgio E, Vaula G, Bosco G, et al. Two families with novel missense mutations in COL4A1: when diagnosis can be missed. J Neurol Sci 2015;352(1-2):99-104. PMID 25873210
19: Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 2005;308(5725):1167-71.** PMID 15905400
20: Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006;354(14):1489-96.** PMID 16598045
21: Govaert P. Prenatal stroke. Semin Fetal Neonatal Med 2009;14(5):250-66. PMID 19664975
22: Granata T, Battaglia G. Schizencephaly. Handb Clin Neurol 2007;87:235-46. PMID 18809029
23: Grossi A, Severino M, Rusmini M, et al. Targeted re-sequencing in pediatric and perinatal stroke. Eur J Med Genet 2020;63(11):104030. PMID 32818659
24: Gubana F, Christov C, Coste T, et al. Prenatal diagnosis of COL4A1 mutations in eight cases: further delineation of the neurohistopathological phenotype. Pediatr Dev Pathol 2022;25(4):435-46. PMID 35382634
25: Gunda B, Mine M, Kovács T, et al. COL4A2 mutation causing adult onset recurrent intracerebral hemorrhage and leukoencephalopathy. J Neurol 2014;261(3):500-3. PMID 24390199
26: Ha TT, Sadleir LG, Mandelstam SA, et al. A mutation in COL4A2 causes autosomal dominant porencephaly with cataracts. Am J Med Genet A 2016;170A(4):1059-63. PMID 26708157
27: Harada T, Uegaki T, Arata K, Tsunetou T, Taniguchi F, Harada T. Schizencephaly and porencephaly due to fetal intracranial hemorrhage: a report of two cases. Yonago Acta Med 2018;60(4):241-5. PMID 29434494
28: Heschl R. Gehirndefect und hydrocephalus. Vierteljahresschr Prakt Heilkd 1859;61:59-74.
29: Hino-Fukuyo N, Kikuchi A, Iwasaki M, et al. Dramatic response after functional hemispherectomy in a patient with epileptic encephalopathy carrying a de novo COL4A1 mutation. Brain Dev 2017;39(4):337-40. PMID 27916450
30: Hino-Fukuyo N, Togashi N, Takahashi R, et al. Neuroepidemiology of porencephaly, schizencephaly, and hydranencephaly in Miyagi Prefecture, Japan. Pediatr Neurol 2016;54:39-42. PMID 26545857
31: Husain T, Langlois PH, Sever LE, Gambello MJ. Descriptive epidemiologic features shared by birth defects thought to be related to vascular disruption in Texas, 1996-2002. Birth Defects Res A Clin Mol Teratol 2008;82(6):435-40. PMID 18383510
32: Ichikawa N, Usui N, Kondo A, et al. Surgical strategy for refractory epilepsy secondary to porencephaly: ictal SPECT may obviate the need for intracranial electroencephalography. Patient series. J Neurosurg Case Lessons 2021;1(21):CASE21121. PMID 35854864
33: Itai T, Miyatake S, Taguri M, et al. Prenatal clinical manifestations in individuals with COL4A1/2 variants. J Med Genet 2021;58(8):505-13. PMID 32732225
34: Jeanne M, Labelle-Dumais C, Jorgensen J, et al. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. Am J Hum Genet 2012;90(1):91-101. PMID 22209247
35: Khoshnoodi J, Pedchenko V, Hudson BG. Mammalian collagen IV. Microsc Res Tech 2008;71(5):357-70. PMID 18219669
36: Lichtenbelt KD, Pistorius LR, De Tollenaer SM, Mancini GM, De Vries LS. Prenatal genetic confirmation of a COL4A1 mutation presenting with sonographic fetal intracranial hemorrhage. Ultrasound Obstet Gynecol 2012;39(6):726-7. PMID 22223490
37: Livingston J, Doherty D, Orcesi S, et al. COL4A1 mutations associated with a characteristic pattern of intracranial calcification. Neuropediatrics 2011;42(6):227-33. PMID 22134833
38: Lynch JK, Han CJ, Nee LE, Nelson KB. Prothrombotic factors in children with stroke or porencephaly. Pediatrics 2005;116:447-53. PMID 16061602
39: Machino H, Iriyama T, Nakayama T, et al. A case of a surviving co-twin diagnosed with porencephaly and renal hypoplasia after a single intrauterine fetal death at 21 weeks of gestation in a monochorionic monoamniotic twin pregnancy. Oxf Med Case Reports 2017;2017(1):omw096. PMID 28116109
40: Marin-Padilla M. Developmental neuropathology and impact of perinatal brain damage. II: white matter lesions of the neocortex. J Neuropath Exp Neurol 1997;56:219-35.** PMID 9056536
41: Marras CE, Granata T, Franzini A, et al. Hemispherotomy and functional hemispherectomy: indications and outcome. Epilepsy Res 2010;89(1):104-12. PMID 19883995
42: Maurice P, Guilbaud L, Garel J, et al. Prevalence of COL4A1 and COL4A2 mutations in severe fetal multifocal hemorrhagic and/or ischemic cerebral lesions. Ultrasound Obstet Gynecol 2021;57(5):783-9. PMID 32515830
43: McGovern M, Flanagan O, Lynch B, Lynch SA, Allen NM. Novel COL4A2 variant in a large pedigree: consequences and dilemmas. Clin Genet 2017;92(4):447-8. PMID 28542708
44: Meuwissen ME, Halley DJ, Smit LS, et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet Med 2015;17(11):843-53.** PMID 25719457
45: Miyatake S, Schneeberger S, Koyama N, et al. Biallelic COLGALT1 variants are associated with cerebral small vessel disease. Ann Neurol 2018;84(6):843-53. PMID 30412317
46: Nagarajan L, Ghosh S, Palumbo L, Lee S, Shipman P, Dyke J. Discordant electroencephalogram epileptiform activity and hemispherectomy in children with refractory epilepsy and encephaloclastic lesions: a case series. Dev Med Child Neurol 2022;64(3):387-94. PMID 34495552
47: Neri S, Ferlazzo E, Africa E, et al. Novel COL4A2 mutation causing familial malformations of cortical development. Eur Rev Med Pharmacol Sci 2021;25(2):898-905. PMID 33577044
48: Ogura H, Ohga S, Aoki T, et al. Novel COL4A1 mutations identified in infants with congenital hemolytic anemia in association with brain malformations. Hum Genome Var 2020;7(1):42. PMID 33298904
49: Oommen AT, Sethy G, Minz NT, Patra J, Panda SS. Unusual presentation of porencephalic cyst in an adult. J Clin Diagn Res 2017;11(2):OD12-13. PMID 28384919
50: Plaisier E, Ronco P. COL4A1-related disorders. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® [Internet]. Seattle: University of Washington, 2016.**
51: Poschl E, Schlötzer-Schrehardt U, Brachvogel B, Saito K, Ninomiya Y, Mayer U. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 2004;131(7):1619-28. PMID 14998921
52: Qureshi A, Jehangir A, York EP. Porencephalic cyst: a rare cause of new-onset seizure in an adult. J Community Hosp Intern Med Perspect 2018;8(2):92-3. PMID 29686797
53: Sananès N, Gabriele V, Weingertner A, et al. Evaluation of long-term neurodevelopment in twin-twin transfusion syndrome after laser therapy. Prenat Diagn 2016;36(12):1139-45. PMID 27764900
54: Sarnat HB. Cerebral dysgenesis. Embryology and clinical expression. New York: Oxford Univ Pr, 1992:89-133.**
55: Sarnat HB, Flores-Sarnat L. Radial microcolumnar cortical architecture: maturational arrest or cortical dysplasia? Pediatr Neurol 2013;48(4):259-70.** PMID 23498558
56: Sato T, Kato M, Moriyama K. A case of tubulinopathy presenting with porencephaly caused by a novel missense mutation in the TUBA1A gene. Brain Dev 2018b;40(9):819-23. PMID 29907476
57: Sato Y, Shibasaki J, Aida N, et al. Novel COL4A1 mutation in a fetus with early prenatal onset of schizencephaly. Hum Genome Var 2018a;5:4. PMID 29760938
58: Scheuerle AE, Aylsworth AS. Birth defects and neonatal morbidity caused by teratogen exposure after the embryonic period. Birth Defects Res A Clin Mol Teratol 2016;106(11):935-9. PMID 27511745
59: Schramm J, Kuczaty S, Sassen R, Elger CE, von Lehe M. Pediatric functional hemispherectomy: outcome in 92 patients. Acta Neurochir (Wien) 2012;154(11):2017-28. PMID 22941395
60: Shah S, Ellard S, Kneen R, et al. Childhood presentation of COL4A1 mutations. Dev Med Child Neurol 2012;54(6):569-74. PMID 22574627
61: Shannon P, Hum C, Parks T, et al. Brain and placental pathology in fetal COL4A1 related disease. Pediatr Dev Pathol 2021;24(3):175-86. PMID 33475042
62: Sherlock RL, Synnes AR, Grunau RE, et al. Long-term outcome after neonatal intraparenchymal echodensities with porencephaly. Arch Dis Child Fetal Neonatal Ed 2008;93(2):F127-31. PMID 17704104
63: Shimizu M, Maeda T, Izumi T. The differences in epileptic characteristics in patients with porencephaly and schizencephaly. Brain Dev 2012;34(7):546-52. PMID 22024697
64: Straka B, Vlčková M, Libá Z, et al. COL4A1 mutation-related disorder presenting as fetal intracranial bleeding, hydrocephalus, and polymicrogyria. Epilepsia Open 2023;8(1):211-6. PMID 36504316
65: Takenouchi T, Ohyagi M, Torii C, Kosaki R, Takahashi T, Kosaki K. Porencephaly in a fetus and HANAC in her father: variable expression of COL4A1 mutation. Am J Med Genet A 2015;167A(1):156-8. PMID 25425218
66: Teunissen MWA, Kamsteeg EJ, Sallevelt SCEH, et al. Biallelic variants in the COLGALT1 gene causes severe congenital porencephaly: a case report. Neurol Genet 2021;7(2):e564. PMID 33709034
67: Tonni G, Ferrari B, Defelice C, Centini G. Neonatal porencephaly in very low birth weight infants: ultrasound timing of asphyxial injury and neurodevelopmental outcome at two years of age. J Matern Fetal Neonatal Med 2005;18(6):361-5. PMID 16390800
68: Uvebrant P. Hemiplegic cerebral palsy: aetiology and outcome. Acta Paediatr Scand 1988;345(Suppl):1-100.** PMID 3201989
69: Vahedi K, Alamowitch S. Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease. Curr Opin Neurol 2011;24(1):63-8.** PMID 21157337
70: Vahedi K, Kubis N, Boukobza M, et al. COL4A1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage. Stroke 2007;38(5):1461-4. PMID 17379824
71: Van Agtmael T, Bailey MA, Schlötzer-Schrehardt U, et al. Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume. Hum Mol Genet 2010;19(6):1119-28. PMID 20056676
72: Verbeek E, Meuwissen ME, Verheijen FW, et al. COL4A2 mutation associated with familial porencephaly and small-vessel disease. Eur J Hum Genet 2012;20(8):844-51. PMID 22333902
73: Yoneda Y, Haginoya K, Arai H, et al. De novo and inherited mutations in COL4A2, encoding the type IV collagen α2 chain cause porencephaly. Am J Hum Genet 2012;90:86-90. PMID 22209246
74: Yoneda Y, Haginoya K, Kato M, et al.Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly. Ann Neurol 2013;73(1):48-57. PMID 23225343
75: Wang QH, Zou LP, Zhang MN, et al. Phenotypic characterization of COL4A1-related West syndrome. Epilepsy Res 2020;164:106349. PMID 32446163
76: Williams T, Wilkinson AG, Kandasamy J, Cooper S, Boardman JP. Antenatal diagnosis of intracranial haemorrhage and porencephalic cyst. BMJ Case Rep 2015;2015. PMID 25716048
77: Zagaglia S, Selch C, Nisevic JR, et al. Neurologic phenotypes associated with COL4A1/2 mutations: expanding the spectrum of disease. Neurology 2018;91(22):e2078-88. PMID 30413629

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Tiziana Granata MD

Dr. Granata of the Fondazione Istituto Nazionale Neurologico Carlo Besta in Milan, Italy, has no relevant financial relationships to disclose.
See Profile

Editor

Harvey B Sarnat MS MD FRCPC

Dr. Sarnat of the University of Calgary has no relevant financial relationships to disclose.
See Profile

Former Authors

Geoffrey Miller MD (original author) and Giorgio Battaglia MD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Porencephaly, congenital, developmental: 742.4

Porencephaly, acquired, nondevelopmental: 348.0
ICD-10: Porencephaly: Q04.6

Porencephalic cyst, acquired: G93.0
OMIM: Familial porencephaly: #175780

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Porencephaly

Associated Disorders

Absence of septum pellucidum
Cerebral palsy
Congenital infection
Epilepsy
Infantile spasms
- Intracranial hemorrhage
- Ischemic necrosis
- Mental retardation
- Periventricular hemorrhagic infarction
- Polymicrogyria
- Prematurity
- West syndrome

Differential Diagnosis

schizencephaly
encephaloclastic porencephalies
clastic brain damage due to prenatal stroke
multicystic encephalomalacia
hydranencephaly
- basket brain
- arachnoid cyst

Also Relevant

Cerebral palsy
Epidermal nevus syndromes: neurologic phenotypes
Epilepsy
Intellectual disability
Oral-facial-digital syndromes
- Polymicrogyria
- Schizencephaly
- Septo-optic-pituitary dysplasia complex
- West syndrome

Porencephaly

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Genetic counseling

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Cerebro-oculo-facio-skeletal syndrome

Schizencephaly

Fetal anticonvulsant syndrome

Rhombencephalosynapsis

Malformations of the brain

Von Hippel-Lindau disease

Vein of Galen malformations

This is an article preview.
Start a Free Account
to access the full version.